These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 18679173)

  • 1. Evoking plasmin for beta-amyloid clearance.
    Zhao J; Pei G
    Cell Res; 2008 Aug; 18(8):803-4. PubMed ID: 18679173
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain.
    Fabbro S; Seeds NW
    J Neurochem; 2009 Apr; 109(2):303-15. PubMed ID: 19222708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity.
    Van Nostrand WE; Porter M
    Biochemistry; 1999 Aug; 38(35):11570-6. PubMed ID: 10471309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease: treatments in discovery and development.
    Citron M
    Nat Neurosci; 2002 Nov; 5 Suppl():1055-7. PubMed ID: 12403985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells.
    Kazmierczak A; Strosznajder JB; Adamczyk A
    Neurochem Int; 2008 Dec; 53(6-8):263-9. PubMed ID: 18804502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolysis in Alzheimer's disease. Can plasmin tip the balance?
    Periz G; Fortini ME
    EMBO Rep; 2000 Dec; 1(6):477-8. PubMed ID: 11263489
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
    Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
    J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-amyloid and glutamate receptors.
    Gasparini L; Dityatev A
    Exp Neurol; 2008 Jul; 212(1):1-4. PubMed ID: 18448101
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of fibronectin type I domains as amyloid-binding modules on tissue-type plasminogen activator and three homologs.
    Maas C; Schiks B; Strangi RD; Hackeng TM; Bouma BN; Gebbink MF; Bouma B
    Amyloid; 2008 Sep; 15(3):166-80. PubMed ID: 18925455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.
    Ledesma MD; Da Silva JS; Crassaerts K; Delacourte A; De Strooper B; Dotti CG
    EMBO Rep; 2000 Dec; 1(6):530-5. PubMed ID: 11263499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Alzheimer disease and cholesterol].
    Yanagisawa K
    No To Shinkei; 1999 Feb; 51(2):116-24. PubMed ID: 10198900
    [No Abstract]   [Full Text] [Related]  

  • 13. Statins may act through increasing tissue plasminogen activator/plasmin activity to lower risk of Alzheimer's disease.
    Tsai SJ
    CNS Spectr; 2009 May; 14(5):234-5. PubMed ID: 19407721
    [No Abstract]   [Full Text] [Related]  

  • 14. [New knowledge about amyloid can result in new treatment of Alzheimer disease].
    Jönhagen ME
    Lakartidningen; 2005 Oct 24-30; 102(43):3104-5. PubMed ID: 16302503
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-d-aspartate receptor signaling.
    Shimazawa M; Inokuchi Y; Okuno T; Nakajima Y; Sakaguchi G; Kato A; Oku H; Sugiyama T; Kudo T; Ikeda T; Takeda M; Hara H
    J Neurochem; 2008 Oct; 107(1):279-90. PubMed ID: 18691390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biology and pathobiology of the intramembrane proteolysis by gamma-secretase].
    Tomita T
    Tanpakushitsu Kakusan Koso; 2009 Oct; 54(13):1747-53. PubMed ID: 19827607
    [No Abstract]   [Full Text] [Related]  

  • 18. [Endoplasmic reticulum and Alzheimer's disease].
    Tang K; Zhang JT
    Sheng Li Ke Xue Jin Zhan; 2001 Oct; 32(4):347-9. PubMed ID: 12545867
    [No Abstract]   [Full Text] [Related]  

  • 19. [Presymptomatic diagnosis, prevention and therapy].
    Iwata N; Higuchi M; Saito T; Saido TC
    No To Shinkei; 2005 Oct; 57(10):855-66. PubMed ID: 16277230
    [No Abstract]   [Full Text] [Related]  

  • 20. S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters.
    Lin HC; Hsieh HM; Chen YH; Hu ML
    Neurotoxicology; 2009 Jul; 30(4):622-7. PubMed ID: 19635394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.